- Home
- KRYS vs JHG Comparison
KRYS vs JHG Comparison
Compare KRYS & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRYS | JHG |
|---|---|---|
| Founded | 2015 | 1934 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.0B |
| IPO Year | 2017 | 2003 |
Fundamental Metrics
Financial Performance| Metric | KRYS | JHG |
|---|---|---|
| Price | $345.32 | $51.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $297.60 | $48.29 |
| AVG Volume (30 Days) | 242.1K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.33% |
| EPS Growth | ★ 128.00 | 104.30 |
| EPS | ★ 1.83 | 0.59 |
| Revenue | $389,130,000.00 | ★ $1,743,700,000.00 |
| Revenue This Year | $38.74 | N/A |
| Revenue Next Year | $32.53 | $6.21 |
| P/E Ratio | $186.02 | ★ $87.80 |
| Revenue Growth | 33.94 | ★ 74.39 |
| 52 Week Low | $130.17 | $38.42 |
| 52 Week High | $347.67 | $53.76 |
Technical Indicators
Market Signals| Indicator | KRYS | JHG |
|---|---|---|
| Relative Strength Index (RSI) | 73.08 | 60.24 |
| Support Level | $253.89 | $51.72 |
| Resistance Level | N/A | $52.49 |
| Average True Range (ATR) | 12.58 | 0.07 |
| MACD | 3.13 | -0.00 |
| Stochastic Oscillator | 86.78 | 79.55 |
Price Performance
Historical ComparisonAbout KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
About JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (49% of managed assets), self-directed (20%) and institutional (31%) clients. At the end of 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $493.2 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (65%), with customers from Europe, the Middle East, Africa, and Latin America (26%) and the Asia-Pacific region (9%) accounting for the remainder.